Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Celecoxib is a nonsteroidal anti-inflammatory drug
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Subscribe To Our Newsletter & Stay Updated
